TY  - CHAP
M1  - Book, Section
TI  - Treatment of Non–Small-Cell Lung Cancer: Chemotherapy and Immunotherapy
A1  - Carr, Laurie L.
A2  - Grippi, Michael A.
A2  - Antin-Ozerkis, Danielle E.
A2  - Dela Cruz, Charles S.
A2  - Kotloff, Robert M.
A2  - Kotton, Camille Nelson
A2  - Pack, Allan I.
Y1  - 2023
N1  - 
T2  - Fishman’s Pulmonary Diseases and Disorders, 6e
AB  - Although  lung  cancer  remains  the  leading  cause  of  cancer  death  in  the  United  States,  a  reduction  in  smoking  rates  and  recent  medical  advances  have  improved  the  overall  mortality  rate.  The  decline  in  lung  cancer  mortality  rates  has  accelerated  from  a  3%  decrease  (2008–2013)  to  5%  (2013–2017).1  Noted  medical  advances  driving  the  decrease  include  lung  cancer  screening  and  stereotactic  body  radiotherapy.  However,  improved  systemic  therapy  with  immune  checkpoint  inhibitors  and  targeted  agents  also  have  had  an  impact.  These  improvements  have  led  to  prolonged  survival  in  those  with  metastatic  disease.  Treatment  with  targeted  agents  or  immunotherapy  has  led  to  a  significant  percentage  of  these  patients  surviving  5  years  or  more.2–4  These  novel  therapies  have  emerged  to  make  lung  cancer  therapy  better  tolerated  and  more  effective,  even  among  those  with  significant  comorbidities.  Thus,  although  the  morbidity  and  mortality  of  lung  cancer  remain  high,  novel  approaches  to  therapy  have  begun  to  make  a  substantial  impact.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1195013279
ER  -